Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.09Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balances meaningful operational and commercial progress (record Q4 revenue, installed base growth, strong recurring revenue, reagent and service momentum, product launches and digital adoption) against significant near-term financial and margin headwinds (GAAP net losses amplified by a large deferred tax valuation allowance, margin compression from tariffs and manufacturing transition, increased operating expenses and lower adjusted EBITDA). Management provided cautious optimism with 2026 guidance ($205M–$212M) reflecting continued recovery but retained contingencies for uncertainty.Company Guidance
Q4 Record Revenue and Sequential Acceleration
Fourth quarter 2025 revenue of $62.1 million, up 8% year-over-year, the highest revenue historically recorded by Cytek; company achieved sequential acceleration through 2025 (Q1 -8% YoY, Q2 -2%, Q3 +2%, Q4 +8%).
Full Year Revenue Growth and Return to Growth in H2
Full year 2025 revenue of $201.5 million, up 1% year-over-year; second half 2025 revenue up ~5% vs. second half 2024, reflecting a pivot from H1 weakness to H2 growth.
Installed Base and Unit Volume Expansion
Installed base increased by 208 instruments in Q4 to 3,664 units; unit volume grew 22% for 2025 vs prior year and accelerated to 26% growth in Q4 year-over-year.
Successful New Product Launches and Awards
Aurora Evo launched in May 2025 and contributed to 21% unit growth in the combined Aurora category in Q4 vs Q4 2024; Muse Micro System received 2025 Biotech Breakthrough Award (Drug Discovery Solution of the Year).
Strong Recurring Revenue and Service Momentum
Recurring revenue represented 34% of total revenue for 2025 and grew 21% year-over-year; service revenue grew 25% in Q4 and ~21% for the full year, driven by installed base growth and higher usage.
Reagents and Applications Growth
Reagent revenue grew more than 20% in Q4 in all geographic regions except the U.S., and grew >25% for full year 2025, supported by faster delivery times, expanded catalog and dedicated sales efforts.
Digital / Bioinformatics Adoption
Cytek Cloud users grew to over 24,000 by year-end 2025, an increase of more than 50% YoY, representing nearly 8 users per installed FSP instrument and supporting reagent and service uptake.
Operational Actions and Balance Sheet
New Singapore manufacturing facility began generating revenue in under 100 days, supporting regional manufacturing strategy; cash, cash equivalents and marketable securities totaled $261.5 million at Dec 31, 2025, and the company repurchased $15.1 million of stock during 2025.
CTKB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CTKB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $4.40 | $4.48 | +1.82% |
Nov 05, 2025 | $4.01 | $4.54 | +13.22% |
Aug 06, 2025 | $3.89 | $4.11 | +5.66% |
May 08, 2025 | $3.79 | $2.92 | -22.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cytek Biosciences (CTKB) report earnings?
Cytek Biosciences (CTKB) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Cytek Biosciences (CTKB) earnings time?
Cytek Biosciences (CTKB) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTKB EPS forecast?
CTKB EPS forecast for the fiscal quarter 2026 (Q1) is -0.09.